DURHAM, N.C. and ST. LOUIS, Feb. 20 /PRNewswire/ -- bioMerieux, Inc., a world leader in the field of in vitro diagnostics, will kick off its third annual Innovation in Motion bus tour this month. The fully equipped mobile laboratory and theater will embark on a six-month journey, bringing more product training, education and certification straight to its customers. The tour will visit more than 50 cities, beginning February 19th.
The goal of the Innovation in Motion tour is to deliver added benefits to bioMerieux customers through educational seminars and interactive product training. Particularly for small and mid-sized hospitals, the bus tour is important because it provides ready access to some of the newest equipment and advanced technology for hospitals.
“We want to make it very convenient to earn professional education credit and receive in-depth product demonstrations and training,” said Herb Steward, Executive Vice President and General Manager for bioMerieux North America. “This enhanced educational experience will maximize lab performance and empower clinical decision making, ultimately improving the fast and accurate diagnosis of disease.”
The Innovation in Motion lab will feature several bioMerieux products. TEMPO(R) and DiversiLab(R) are two of the newest products from bioMerieux. TEMPO is the first automated quality indicator testing system for the food industry. The system offers enumeration of quality indicators, which are vital in determining overall product hygiene. DiversiLab automates the process for tracking the source and spread of microbial infection or contamination. DiversiLab offers faster, more precise solutions that are easier to implement in order to determine the source of an outbreak, understand how it spreads, take the necessary steps to control it, and monitor its epidemiology. DiversiLab serves both the clinical and industrial markets, tracking hospital- acquired infections (nosocomial) and providing quality control for food safety.
Additionally, bioMerieux will offer interactive training for other popular products, including VITEK(R) 2, STELLARA(R), BacT/ALERT(R) 3D, and NucliSENS(R) easyMAG(TM). Onboard demonstrations will illustrate rapid results, increased productivity, automated bacterial identification, extensive clinical intervention, and improved safety.
bioMerieux’s automated products are designed to seamlessly work together, providing clinically relevant data to improve patient care. BacT/ALERT 3D performs microbial detection and VITEK 2 provides fully automated bacterial identification and antibiotic susceptibility. STELLARA, patient therapy management software, then integrates real-time microbiology results from BacT/ALERT 3D and VITEK 2 systems and communicates directly to the clinician for quicker and more accurate treatment decisions. Streamlining these processes can positively impact patients and the hospital. bioMerieux refers to these products as Integrated Solutions.
Beginning this spring, bus tour attendees will have the opportunity to earn continuing education credits. Professional Achievement in Continuing Education (PACE) credits will be offered on a variety of topics from recent bioMerieux Knowledge Forums at industry trade shows. Topics include antibiotic stewardship, microbial genotyping, data driven drug decisions, and molecular testing for your lab. The onboard laptop lounge allows attendees to arrange immediate email delivery of PACE credit approvals.
The Innovation in Motion tour begins in Springdale, Arkansas and will crisscross the country before wrapping up at bioMerieux’s Durham, N.C. headquarters in late July. For more information, visit http://www.biomerieux-usa.com/inmotion.
About bioMerieux, Inc.
bioMerieux is a leading international diagnostics group that specializes in the field of in vitro diagnostics for clinical and industrial applications. bioMerieux designs, develops, manufactures and markets systems (i.e. reagents, instruments and software) used in:
- Clinical applications: the diagnosis of infectious diseases such as hepatitis, HIV, tuberculosis and respiratory illnesses, as well as pathologies such as cardiovascular diseases and cancer, based on the analysis of biological samples (such as blood, saliva or urine); and - Industrial applications: the microbiological analysis of food, environments (such as water and air), surfaces and pharmaceutical and cosmetic products, based on the analysis of product or environmental samples.
In 2006, bioMerieux sales reached 1,037 million euros. The company is present in more than 150 countries through 35 subsidiaries and a large network of distributors. bioMerieux is listed on the Eurolist of Euronext, Paris (FR0010096479 - BIM). See http://www.biomerieux-usa.com for more information.
bioMerieux, Inc.
CONTACT: Paige Sargent of French-West-Vaughan, +1-919-277-1162, orpsargent@fwv-us.com, for bioMerieux, Inc.; or Christelle Chabert-Toujas ofbioMerieux, +33 (0)4 78 87 52 01, orchristelle.chabert-toujas@eu.biomerieux.com, or Investor Relations, HerveLaurent of bioMerieux, +33 (0)4 78 87 22 37, orinvestor.relations@eu.biomerieux.com
